Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports

被引:23
|
作者
Ueda, Natsumi [1 ]
Umetsu, Ryogo [1 ]
Abe, Junko [1 ,2 ]
Kato, Yamato [1 ]
Nakayama, Yoko [1 ]
Kato, Zenichiro [3 ]
Kinosada, Yasutomi [4 ]
Nakamura, Mitsuhiro [1 ]
机构
[1] Gifu Pharmaceut Univ, Lab Drug Informat, Gifu 5011196, Japan
[2] Med Database Co Ltd, Shibuya Ku, Tokyo 1500011, Japan
[3] Gifu Univ, Grad Sch Med, Dept Pediat, Gifu 5011194, Japan
[4] Gifu Univ, Grad Sch Med, Dept Biomed Informat, Gifu 5011194, Japan
关键词
oseltamivir; abnormal behavior; adverse event report; GENDER-DIFFERENCES; DRUG-REACTIONS; INFLUENZA; DISPROPORTIONALITY; PHARMACOVIGILANCE; CHILDREN; ADHD; PET;
D O I
10.1248/bpb.b15-00253
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There have been concerns that oseltamivir causes neuropsychiatric adverse events (NPAEs). We analyzed the association of age and gender with NPAEs in patients treated with oseltamivir using a logistic regression model. NPAE data were obtained from the U.S. Food and Drug Administration Adverse Event Reporting System (2004 to 2013). The lower limit of the reporting odds ratio (ROR) 95% confidence interval (CI) of "abnormal behavior" in Japan, Singapore, and Taiwan was >= 1 The effects of the interaction terms for oseltamivir in male patients aged 10-19 years were statistically significant. The adjusted ROR of "abnormal behavior" was 96.4 (95% CI, 77.5-119.9) in male patients aged 10-19 years treated with osletamivir. In female patients, the results of the likelihood ratio test for "abnormal behavior" were not statistically significant. The adjusted NPAE RORs were increased in male and female patients under the age of 20 years. Oseltamivir use could be associated with "abnormal behavior" in males aged 10-19 years. After considering the causality restraints of the current analysis, further epidemiological studies are recommended.
引用
收藏
页码:1638 / 1644
页数:7
相关论文
共 50 条
  • [1] Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment
    Smith, J. R.
    Sacks, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (04) : 596 - 605
  • [2] Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir A Comprehensive Review
    Toovey, Stephen
    Rayner, Craig
    Prinssen, Eric
    Chu, Tom
    Donner, Barbara
    Thakrar, Bharat
    Dutkowski, Regina
    Hoffmann, Gerhard
    Breidenbach, Alexander
    Lindemann, Lothar
    Carey, Ellen
    Boak, Lauren
    Gieschke, Ronald
    Sacks, Susan
    Solsky, Jonathan
    Small, Ian
    Reddy, David
    [J]. DRUG SAFETY, 2008, 31 (12) : 1097 - 1114
  • [3] Neuropsychiatric Adverse Events and Oseltamivir for Prophylaxis
    Mark Jones
    Rokuro Hama
    Tom Jefferson
    Peter Doshi
    [J]. Drug Safety, 2012, 35 : 1187 - 1188
  • [4] Neuropsychiatric Adverse Events and Oseltamivir for Prophylaxis
    Jones, Mark
    Hama, Rokuro
    Jefferson, Tom
    Doshi, Peter
    [J]. DRUG SAFETY, 2012, 35 (12) : 1187 - 1188
  • [5] Neuropsychiatric Adverse Events and Oseltamivir for Prophylaxis Reply
    Toovey, Stephen
    [J]. DRUG SAFETY, 2012, 35 (12) : 1188 - 1190
  • [6] ADVERSE EFFECTS OF OSELTAMIVIR Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012
    Hoffman, Keith B.
    Demakas, Andrea
    Erdman, Colin B.
    Dimbil, Mo
    Doraiswamy, P. Murali
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
  • [7] Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review
    Stephen Toovey
    Eric P. Prinssen
    Craig R. Rayner
    Bharat T. Thakrar
    Regina Dutkowski
    Annette Koerner
    Tom Chu
    Alexandra Sirzen-Zelenskaya
    Markus Britschgi
    Sudhir Bansod
    Barbara Donner
    [J]. Advances in Therapy, 2012, 29 : 826 - 848
  • [8] Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review
    Toovey, Stephen
    Prinssen, Eric P.
    Rayner, Craig R.
    Thakrar, Bharat T.
    Dutkowski, Regina
    Koerner, Annette
    Chu, Tom
    Sirzen-Zelenskaya, Alexandra
    Britschgi, Markus
    Bansod, Sudhir
    Donner, Barbara
    [J]. ADVANCES IN THERAPY, 2012, 29 (10) : 826 - 848
  • [9] Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
    Kato Y.
    Umetsu R.
    Abe J.
    Ueda N.
    Nakayama Y.
    Kinosada Y.
    Nakamura M.
    [J]. Journal of Pharmaceutical Health Care and Sciences, 1 (1)